Previous case reports indicate that secondary AML transformed from essential thrombocytosis or myelofibrosis particularly benefit from IFNα therapy (Berneman et al. 2010; Dagorne et al. 2013). This evidence concerns the gene IFNA2 and essential thrombocythemia.